Jon Hamilton

Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.

In 2014, Hamilton went to Liberia as part of the NPR team that covered Ebola. The team received a Peabody Award for its coverage.

Following the 2011 earthquake and tsunami in Japan, Hamilton was part of NPR's team of science reporters and editors who went to Japan to cover the crisis at the Fukushima Dai-ichi nuclear power plant.

Hamilton contributed several pieces to the Science Desk series "The Human Edge," which looked at what makes people the most versatile and powerful species on Earth. His reporting explained how humans use stories, how the highly evolved human brain is made from primitive parts, and what autism reveals about humans' social brains.

In 2009, Hamilton received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism.

Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He reported on states that have improved their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.

From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.

Hamilton graduated with honors from Oberlin College in Ohio with a Bachelor of Arts in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University, where he graduated with honors. During his time at Columbia, Hamilton was awarded the Baker Prize for magazine writing and earned a Sherwood traveling fellowship.

Medical research was an early casualty of the COVID-19 pandemic.

After cases began emerging worldwide, thousands of clinical trials unrelated to COVID-19 were paused or canceled amid fears that participants would be infected. But now some researchers are finding ways to carry on in spite of the coronavirus.

Researchers appear to have shown how the brain creates two different kinds of thirst.

The process involves two types of brain cells, one that responds to a decline in fluid in our bodies, while the other monitors levels of salt and other minerals, a team reports in the journal Nature.

Together, these specialized thirst cells seem to determine whether animals and people crave pure water or something like a sports drink, which contains salt and other minerals.

Mental illness can run in families. And Dr. Kafui Dzirasa grew up in one of these families.

His close relatives include people with schizophrenia, bipolar disorder and depression. As a medical student, he learned about the ones who'd been committed to psychiatric hospitals or who "went missing" and were discovered in alleyways.

Dzirasa decided to dedicate his career to "figuring out how to make science relevant to ultimately help my own family."

Out-of-body experiences are all about rhythm, a team reported Wednesday in the journal Nature.

In mice and one person, scientists were able to reproduce the altered state often associated with ketamine by inducing certain brain cells to fire together in a slow, rhythmic fashion.

Some mighty mice have overcome one of the major obstacles to interplanetary space flight: muscle and bone loss.

The mice got a drug that prevented the usual decreases in muscle and bone mass during a month on the International Space Station, a team reports in the journal Proceedings of the National Academy of Sciences.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

A combination of two experimental drugs appears to slow the decline of patients with amyotrophic lateral sclerosis, an illness often known as ALS or Lou Gehrig's disease.

A six-month study of 137 patients with a fast-progressing form of the disease found that those who got daily doses of a two-drug combination called AMX0035 scored several points higher on a standard measure of function, a team reports in the Sept. 3 issue of The New England Journal of Medicine.

COVID-19 forced Keriann Wilmot's son to trade his classroom for a computer. It was a tough transition for a 10-year-old with attention deficit hyperactivity disorder.

"It was a different environment for him," Wilmot says. "He wasn't used to this kind of work from school coming in the format of an email in his Chromebook every single day."

The Food and Drug Administration has approved a variant of the anesthetic and party drug ketamine for suicidal patients with major depression.

The drug is a nasal spray called Spravato and it contains esketamine, a chemical cousin of ketamine.

This is the story of a fatal genetic disease, a tenacious scientist and a family that never lost hope.

Conner Curran was 4 years old when he was diagnosed with Duchenne muscular dystrophy, a genetic disease that causes muscles to waste away.

Conner's mother, Jessica Curran, remembers some advice she got from the doctor who made that 2015 diagnosis: "Take your son home, love him, take him on trips while he's walking, give him a good life and enjoy him because there are really not many options right now."

For years, public health officials have been trying to dispel the myth that people who get a flu shot are more likely to get Alzheimer's disease.

They are not. And now there is evidence that vaccines that protect against the flu and pneumonia may actually protect people from Alzheimer's, too.

The same process that causes dew drops to form on a blade of grass appears to play an important role in Alzheimer's disease and other brain diseases.

Scientists are monitoring the virus that causes COVID-19 for genetic changes that could make a vaccine ineffective. But so far, they're not seeing any.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Three research institutions in Seattle have joined forces to study how Alzheimer's disease takes root in the brain.

The consortium will create a new research center at the Allen Institute for Brain Science to study tissue from brains donated by people who died with Alzheimer's.

A neurologist who encased his healthy right arm in a pink fiberglass cast for two weeks has shown how quickly the brain can change after an injury or illness.

Daily scans of Dr. Nico Dosenbach's brain showed that circuits controlling his immobilized arm disconnected from the body's motor system within 48 hours.

But during the same period, his brain began to produce new signals seemingly meant to keep those circuits intact and ready to reconnect quickly with the unused limb.

Mounting evidence suggests the coronavirus is more common and less deadly than it first appeared.

The evidence comes from tests that detect antibodies to the coronavirus in a person's blood rather than the virus itself.

The tests are finding large numbers of people in the U.S. who were infected but never became seriously ill. And when these mild infections are included in coronavirus statistics, the virus appears less dangerous.

COVID-19 has given ventilators an undeservedly bad reputation, says Dr. Colin Cooke, an associate professor of medicine in the division of pulmonary and critical care at the University of Michigan.

"It's always disheartening to know that some people are out there saying if you end up on a ventilator it's a death sentence, which is not what we are experiencing — and I don't think it's what the data are showing," Cooke says.

Intensive care teams inside hospitals are rapidly altering the way they care for patients with COVID-19.

The changes range from new protective gear to new treatment protocols aimed at preventing deadly blood clots.

When COVID-19 patients began flooding emergency departments at New York hospitals in March, doctors saw some unusual cases of stroke.

"We had a young woman in her early 30s who came in with a profound stroke, the kind of stroke that leaves someone permanently paralyzed and possibly unable to survive," says Dr. J. Mocco, a professor of neurosurgery and director of the cerebrovascular center at Mount Sinai Health System in New York.

On April 8, David Williams got a standing ovation as he was wheeled out of the John L. McClellan Memorial Veteran's Hospital in Little Rock, Ark.

Williams, 54, a Marine Corps veteran, had survived eight perilous days on a ventilator with COVID-19, and the hospital staff had lined up to give him a joyous, fist-bumping send-off.

Today, Williams is back at home with his wife, D'Anna. But a full recovery remains a distant prospect.

Dr. Wayne Riley, president of SUNY Downstate Health Sciences University, and an NPR science correspondent answer more questions about the racial disparity in how the coronavirus is impacting patients.

Dr. Wayne Riley, president of SUNY Downstate Health Sciences University, and an NPR science correspondent answer questions about the racial disparity in how the coronavirus is impacting patients.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

Pages